Breast Cancer Market in APAC Region Hit $1.9 Billion in 2014 and Will Reach $3.4 Billion by 2021, says GBI Research

Feb 11, 2016, 11:00 ET from GBI Research

LONDON, February 11, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - states that the Asia-Pacific (APAC) breast cancer market will experience considerable expansion from $1.9 billion in 2014 to $3.4 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 8.5%.

Such growth, which will occur across the APAC regions of India, China, Australia, and Japan, will be driven by aging populations, changing lifestyle habits, improved survival rates, and a number of new approvals for drugs that are expected to supplement current market leaders.

Analyst Deekshita Allavarapu says: "It is anticipated that popular drugs, such as Afinitor and Herceptin, will be used in conjunction with several promising breast cancer pipeline treatments. These include abemaciclib, buparlisib, LEE 011, olaparib, and Neuvax, all of which are forecast to be approved by 2021 and have shown significant clinical benefit in trials.

"Such therapies are on the rise due to their increased use in conjunction with chemotherapy. In addition, the strong efficacy profile of targeted therapies has resulted in favorable reimbursement and increased uptake in Japan and Australia. This is despite the drugs' premium pricing, which reflects the cost associated with their development and the significant therapeutic benefit offered."

However, the analyst notes that in India and China, even after premium targeted treatments become available, only patients in the richer territories will be given these drugs, as patients in the poorer districts will not be able to afford them due to a lack of social insurance and inadequately publicly subsidized services.

GBI Research also states that applying for reimbursement for oncology drugs in Australia is becoming more complex due to a time-consuming and complex regulatory and reimbursement process prior to access, which causes a substantial delay in patient access.

"These factors limit the uptake of premium-priced therapies, which somewhat restricts overall breast cancer market growth. Nonetheless, the sheer size of the APAC populations means that, even if a relatively small percentage of patients are eligible for treatment, there will be high levels of revenue," Deekshita concludes.

Sample pages of GBI Research's report Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.      

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter

 

SOURCE GBI Research